StriVectin Revises Ad With NAD-Approved ‘Clear And Conspicuous’ Disclosure
This article was originally published in The Rose Sheet
The National Advertising Division continues work by the FTC in 2014 to crack down on inadequate disclosures, inquiring into a disclaimer used in print advertising for StriVectin Intensive Illuminating Serum. The skin-care firm will use a revised ad going forward that addresses NAD’s concerns about the disclaimer’s placement, clarity and conspicuousness.
You may also be interested in...
P&G emerges largely unscathed from a National Advertising Division dispute regarding claims for Crest Sensi-Stop Strips, which challenger GlaxoSmithKline Consumer Healthcare argued were unsupported, including the product name. NAD determined the firm’s evidence adequate to support claims of immediate relief and protection for up to one month, among other statements made in ads and on product packaging.
FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits. Widely credited as a pioneer that helped create the cosmeceutical category, Strivectin has been warning-free since 2005 when FDA came down on its “Better than Botox?” positioning.
On the heels of FTC’s “Operation Full Disclosure,” which resulted in 60 warning letters, commission officials advise all advertisers to pay close attention to their disclosures and ensure they are clear and conspicuous. The initiative included review of 1,000 national television and print ads, and the agency says it will continue to monitor the advertising landscape for inadequate disclosure use.